Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.9
3.4
Journals
Current Oncology
Special Issues
Therapeutic Advances in Cystectomy for Bladder Cancer
share announcement

Therapeutic Advances in Cystectomy for Bladder Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Genitourinary Oncology".

Deadline for manuscript submissions: 30 June 2026 | Viewed by 864

Special Issue Editor

Dr. Saum B. Ghodoussipour

E-Mail Website
Guest Editor
Rutgers Cancer Institute, Rutgers Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA
Interests: bladder cancer; urologic oncology; surgery

Special Issue Information

Dear Colleagues,

Bladder cancer is a major health concern, and cystectomy is a common treatment option for patients with locally advanced disease. Recently, significant therapeutic breakthroughs have improved outcomes for patients undergoing cystectomy. These include optimized neoadjuvant therapies, surgical techniques, perioperative care protocols, and individualized treatment strategies. The integration of cutting-edge technologies like robotic-assisted surgery has also enhanced surgical precision and patient outcomes. This Special Issue aims to explore and discuss these therapeutic breakthroughs in cystectomy for bladder cancer, offering valuable insights to healthcare professionals and researchers in the field.

We welcome original research articles and reviews on therapeutic advances in cystectomy for bladder cancer, including innovative surgical techniques, novel perioperative therapies, and patient-reported outcomes.

I look forward to receiving your contributions.

Dr. Saum B. Ghodoussipour
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • bladder cancer
  • cystectomy
  • therapeutic advances
  • surgical techniques
  • personalized treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Other

14 pages, 9247 KB  
Case Report
Robotic Partial Cystectomy and Extended Pelvic Lymph Node Dissection for Node-Positive Urachal Adenocarcinoma in a 34-Year-Old Woman: A Case Report
by Stefanie Herrmann, Christian Gilfrich, Stephan Siepmann, Julio Ruben Rodas Garzaro, Fabian Eder, Stephan Schleder, Philipp Aubele, Felix Keil, Matthias May and Anton Kravchuk
Curr. Oncol. 2026, 33(4), 190; https://doi.org/10.3390/curroncol33040190 - 30 Mar 2026
Viewed by 345
Abstract
Urachal carcinoma is a rare and aggressive malignancy for which standardized management remains limited, particularly in patients with locally advanced and node-positive disease. We report the case of a 34-year-old woman with urachal adenocarcinoma involving the bladder dome and radiographically suspicious pelvic lymph [...] Read more.
Urachal carcinoma is a rare and aggressive malignancy for which standardized management remains limited, particularly in patients with locally advanced and node-positive disease. We report the case of a 34-year-old woman with urachal adenocarcinoma involving the bladder dome and radiographically suspicious pelvic lymph nodes who underwent robot-assisted partial cystectomy with urachal resection and extended bilateral pelvic lymph node dissection. Because there was no clinical, radiologic, or intraoperative evidence of umbilical involvement, the umbilicus was preserved after preoperative counseling and intraoperative confirmation of a negative proximal margin. Final pathology demonstrated a 4.5 cm enteric-type urachal adenocarcinoma, pT3a pN2 (2/17), with lymphovascular invasion, perineural invasion, and negative surgical margins. Immunohistochemistry and DNA- and RNA-based next-generation sequencing showed microsatellite stability, mismatch-repair proficiency, low tumor mutational burden, and no actionable genomic alteration. Given the absence of an established adjuvant standard, the multidisciplinary tumor board selected adjuvant FOLFOX as a non-standard postoperative strategy based on the overall clinicopathologic context. The patient remained continent, experienced no postoperative complications or treatment-limiting toxicity, and showed normalization of carcinoembryonic antigen and carbohydrate antigen 19-9 levels. This case provides a carefully contextualized example of transparent surgical reasoning and restrained multidisciplinary management in a rare malignancy with limited prospective evidence. Full article
(This article belongs to the Special Issue Therapeutic Advances in Cystectomy for Bladder Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop